Gilead Sciences, Inc. today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which is studying twice-yearly lenacapavir, the company's ...

Gilead Sciences, Inc. today announced the presentation of new research data from its innovative HIV treatment portfolio and pipeline, including a broad range of data on investigational and marketed ...

The late-breaking poster: Eseba-vec (HB-200) plus pembrolizumab as first-line treatment of recurrent/metastatic ...

Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...

Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

The global hepatitis B diagnostic tests market is on the cusp of substantial expansion, driven by a combination of increasing disease incidence, heightened global awareness campaigns, and rapid ...

As the No.1 University in the world for sport-related subjects, we offer unrivalled research, teaching and partnerships across sport, exercise and health sciences. Our expertise spans the fields of ...

"The global regenerative medicine markets comprises of many key market players competing for markets shares like Novartis AG ...

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter ...

AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...

Maxim downgraded Gilead (GILD) to Hold from Buy. The stock has appreciated significantly following a pullback in the first half of the year, ...

Trump’s newly named WH chief of staff Susie Wiles retained her position as co-chair of the lobbying firm Mercury Public ...